key: cord-0869261-xmkkb3vg authors: Wong, C.; Mansoor, A.; McGinn, T. title: A Cross-sectional Study of Clinical COVID-19 Myocarditis date: 2021-06-08 journal: nan DOI: 10.1101/2021.06.06.21258423 sha: a8313d585596dee263f0c558116516a0d8df175d doc_id: 869261 cord_uid: xmkkb3vg Background: COVID-19 myocarditis is becoming increasingly appreciated as a complication of COVID-19. There are significant hurdles to formal diagnosis with endomyocardial biopsy or cardiac MRI whether by resource limitations, patient instability, or isolation precautions. Therefore, further exploratory analysis is needed to clinically define the characteristics and spectrum of severity of COVID-19 myocarditis. Objectives: The aim of this study was to describe the clinical course, echocardiographic, and laboratory testing across suspected fulminant and non-fulminant clinically defined COVID-19 myocarditis. Methods: In a cross-sectional observational study of 19 patients with clinically defined COVID-19 myocarditis, we report presenting symptoms, clinical course, laboratory findings, and echocardiographic results stratified by non-fulminant and fulminant myocarditis. Student t-test and univariate logistic regression are used to compare laboratory findings across fulminant and non-fulminant cases. Findings: Among 19 patients, there was no prior history of coronary artery disease, atrial fibrillation, or heart failure; 21.1% of patients died; and 78.9% of cases required supplemental oxygen. A significantly higher geometric mean D-dimer and ferritin were observed in patients with fulminant compared to non-fulminant suspected myocarditis. 26.3% of cases had pericardial effusions. 10 out of the 16 with available echocardiographic data had normal left ventricular systolic function. Conclusions: In this cross-sectional analysis, we provide a practical clinical depiction of patients with clinical COVID-19 myocarditis across fulminant and non-fulminant cases. Statistically significant elevations in inflammatory markers in fulminant versus non-fulminant cases generate hypothesis regarding the role of systemic inflammation in driving severity of COVID-19 myocarditis. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. predominantly affects the respiratory system but may also result in myocarditis. 1 binds to the angiotensin converting enzyme-2 receptor expressed on the surface of alveolar and cardiac cells, which may account for the direct cardiac involvement in COVID-19. 2 Myocarditis is an inflammatory disease caused by infectious and non-infectious etiologies. 3 Fulminant myocarditis is the most severe type of myocarditis and is predominantly caused by viral infections. It is characterized by a sudden and severe inflammation of myocardium resulting in cardiogenic shock, ventricular tachyarrhythmias or bradyarrythmias. 3 Clinical presentation of patients with COVID-19 myocarditis varies greatly, but signs and symptoms include fatigue, dyspnea, chest pain, acute-onset heart failure, and cardiogenic shock. 4 Previous studies have reported elevated levels of inflammatory markers, such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), procalcitonin, and lactate. Patients also had elevated levels of troponins and pro-BNP levels. 5 A variety of electrocardiogram (ECG) abnormalities can be seen in patients with myocarditis ranging from ST elevation and PR depression to new-onset bundle branch block, QT prolongation, brady-or tachy-arrhythmias. 6 In patients with clinical suspicion for myocarditis, American Heart Association (AHA) recommends further testing with echocardiogram or cardiovascular magnetic resonance (CMR). 7 On echocardiogram, patients with myocarditis have increased wall thickness, chamber dilation, and pericardial effusion, and ventricular systolic dysfunction. 7 CMR can provide excellent insights into tissue-level pathologies but it's utility is limited by availability and poor image quality with tachycardia, and requirements for deep cleaning after each use in the midst of epidemics and pandemics. The gold standard for diagnosis of myocarditis in endomycardial biopsy (EMB). EMB biopsies are limited due to the risk of contagious spread, the expertise required and false negative rate. 4 They have only been recommended for confirmation of myocarditis in severe cases. 8 Further work is needed to better characterize suspected COVID-19 myocarditis as a clinical entity, because instability, infection control, and resource limitations may prohibit timely, definitive diagnosis by CMR or EMB especially in low-resource settings where the spread of COVID-19 continues. The differential for multiorgan failure and hypotension is overshadowed by ARDS and septic shock; bilateral pulmonary infiltrates are more likely to be All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 8, 2021. ; https://doi.org/10.1101/2021.06.06.21258423 doi: medRxiv preprint attributed to primary pulmonary pathology rather than congestive heart failure; and decreased left ventricular function and troponin elevation may be attributed to demand mediated ischemia or sepsis induced cardiomyopathy. The clinical significance of COVID-19 myocarditis in the majority of cases could be easily overlooked. However, cardiac inflammation with elevated CRP and troponins compared to controls have been noted in patients recovered from COVID-19 and multiple case reports of COVID-19 myocarditis have been previously reported. 9,10 17% of patients with COVID-19 had troponin elevations above the 99th percentile while only 2.9% of patients hospitalized with influenza had troponin elevations. 11, 12 In summary, there is good reason to believe that COVID-19 is uniquely cardiotropic yet the methods for rigorous diagnosis are typically unavailable. COVID-19 myocarditis may be an overlooked clinical entity with potentially significant impact. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 8, 2021. ; https://doi.org/10.1101/2021.06.06.21258423 doi: medRxiv preprint arrest, ventricular tachycardia or fibrillation, atrial fibrillation, intraventricular conduction delay (widened QRS complex), supraventricular tachycardia; elevated troponins; and functional and structural abnormalities on echocardiogram. 13 Patients were excluded if acute coronary syndrome was deemed more likely than myocarditis. 19 of the 41 patients reviewed met these criteria for suspected myocarditis. Cases were categorized as fulminant or non-fulminant where fulminant cases were defined as myocarditis with new onset heart failure requiring ionotropic or mechanical circulatory support. We report the baseline characteristics, outcomes, laboratory findings, and echocardiographic findings of these 19 patients. We report age, sex, body mass index, presence of shortness of breath or chest pain on admission, and supplemental oxygen requirements. Presence of shortness of breath and chest pain were ascertained by chart review of patient's documented symptoms. Supplemental oxygen was defined as either room air, nasal canula, nonrebreather, or intubation. High-flow nasal canula and bilevel positive airway protection were being avoided during the analyzed time period due to infection control policies in response to the pandemic. We also report any recorded history of hypertension, type 2 diabetes, atrial fibrillation, coronary artery disease, heart failure, and chronic kidney. The mean and standard deviation are reported for continuous variables while the counts and percentages are reported for categorical variables. Findings are stratified by fulminant and non-fulminant cases. We report laboratory data at the time of diagnosis. When available, the highest values for troponin, CRP, lactate, D-dimer, ferritin, and procalcitonin within the first 48 hours of clinical COVID-19 myocarditis were recorded. We report troponin as the fold increase of the upper limit of normal because some facilities used troponin I and others troponin T. The upper limit of troponin T was defined as 51 ng/L and the upper limit of troponin I was defined as 15 ng/L. The arithmetic mean and standard deviation are reported for all lab values. We report the geometric mean of the CRP, lactate, D-dimer, ferritin, and procalcitonin. All measurements are stratified by fulminant and non-fulminant myocarditis. We chose to estimate the central tendency of the inflammatory measurements by the geometric mean because these markers represent a multiplicative biologic process of positive feedback loops thought to drive the highly inflammatory state in severe COVID-19. 14 Geometric mean was not reported for troponins because of values equal to 0. Missing data are reported. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The study received expedited IRB approval and was deemed within the scope of IRBapproved data registry for patients with COVID-19 at Northwell Health. Analysis was done with R and the uwintrostats and TableOne packages. myocarditis showed mean age was 58.42 years, 68.4% of patients were male, and mean body mass index was 30.13. There was a lower proportion of males (62.5% v 80%) and a higher average BMI (31.91 v 28.70) in the non-fulminant group. 94.7% patients endorsed shortness of breath on presentation while only 26.3% endorsed chest pain. Chest pain was more common in non-fulminant cases (40% v 11.1%) ( Table 1 ). In terms of cardiovascular risk factors, 52.6% of patients had hypertension and 36.8% had type 2 diabetes. Hypertension and type 2 diabetes tended to be more prevalent in patients with non-fulminant myocarditis (70% v 33.3%; 50% v 22.2%). There was no documented history of atrial fibrillation, coronary artery disease, or prior heart failure. Overall, 21.1% of patients had chronic kidney disease. Regarding their clinical course, a lower proportion of patients with non-fulminant myocarditis were intubated (20% v 66.7%). Overall, 21.1% of All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In exploratory analysis of laboratory findings at the time of suspecting COVID-19 myocarditis, mean fold elevation in troponin above normal limit (100. Table 2) . Descriptive statistics of echocardiographic data shows that all cases of fulminant myocarditis have decreased systolic dysfunction as expected, but ejection fractions less than 40% were not observed (Table 3) . Of the 10 non-fulminant cases, 8 had data on ejection fractions. 4 of these patients had preserved ejection fractions greater than 50% while 2 had ejection fractions between 15% and 40%. Of the 9 cases of suspected fulminant myocarditis, 5 had data on ejection fraction all of which had ejection fractions between 40 and 50%. Only 1 case demonstrated diastolic dysfunction and 5 cases were observed to have pericardial effusions out of 16 cases that were evaluated with echocardiography. In this cross-sectional study of 19 cases of suspected COVID-19 myocarditis, there was no prior history of coronary artery disease, atrial fibrillation, or heart failure; 21.1% of patients died; and 78.9% of cases required supplemental oxygen. In exploratory analysis comparing laboratory values at the time of diagnosis, a significantly higher geometric mean D-dimer and All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The present study characterizes clinical COVID-19 myocarditis through descriptive analysis. Clinical COVID-19 myocarditis is an important entity to characterize because its signs and symptoms overlap with sepsis-induced cardiomyopathy, demand mediated ischemia, and ARDS but it may have unexplored and distinct clinical implications. 4 As a relatively small crosssectional study from a convenience sample, this study is limited to generating hypotheses; statistical inference to a generalized population cannot be made. Significance on hypothesis testing can be interpreted as a measure of statistical extremes that are unlikely to be due purely to chance, which merits further investigation and can motivate variable selection in future studies. On average, troponins were elevated 101 times the normal limit at the time of diagnosis. In prior research, 17% of patients with COVID-19 had troponin elevations above the 99th percentile. 12 Meanwhile, only 2.9% of patients hospitalized with influenza had troponin elevations. 11 The proportion of patients with troponin elevation and the clinical severity of these elevations is notable. In all patients, acute coronary syndrome was not suspected by chart review. This strengthens the hypothesis that cardiac damage is uniquely associated with COVID-19. As the absolute values of troponin elevation are remarkable in this cross-sectional study, further research may investigate the clinical significance of different levels of troponin elevation. The geometric mean but not the arithmetic mean of D-dimer and ferritin were significantly higher in patients with suspected fulminant compared to non-fulminant myocarditis. Direct associations are difficult to infer due to the lack of a randomly sampled population in this study. Still, this raises the hypothesis that fulminant myocarditis may be mediated through higher systemic inflammation. Cases of viral myocarditis have been diagnosed both with and without viral particles observed on endomyocardial biopsy. 15 The observed dose response association between clinical severity of myocarditis and inflammatory markers on a multiplicative scale All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 8, 2021. ; https://doi.org/10.1101/2021.06.06.21258423 doi: medRxiv preprint further motivates investigation into an indirect mechanism of cardiac injury mediated through systemic inflammation. In summary, the present study better characterizes the entity of clinically suspected COVID-19 myocarditis and substantiates the importance of investigating the extent to which COVID-19 is mediated by direct viral injury and/or indirect systemic inflammation through exploratory analysis. Future studies may investigate whether direct versus indirect mechanisms predominate and how this difference impacts clinical outcomes. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Ejection Fraction (n (%)) Missing data 2 (20.0) 1 (11.1) 3 (15.8) Potential Effects of Coronaviruses on the Cardiovascular System: A Review Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) SARS-CoV-2: a potential novel etiology of fulminant myocarditis Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection Diagnostic and prognostic role of electrocardiogram in acute myocarditis: A comprehensive review Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the Myocardial localization of coronavirus in Frequency of troponin elevations in patients with influenza infection during the 2017-2018 influenza season Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases The trinity of COVID-19: immunity, inflammation and intervention A Systematic Review of COVID-19 and Myocarditis No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity